Payment overview · 2025
General Payments
$468.71
22 reported records · 13 companies
Healthcare provider profile · identity verified
Richard L Griffith, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARIETTA, GA · NPI 1528050838
Verified facts
What the public records show
CMS Open Payments records show Richard L Griffith, MD received $468.71 in general payments during 2025 across 22 reported records.
PFIZER INC. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.15 | 26.5% | 5 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.59 | 16.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.55 | 7.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.92 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.16 | 6.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $29.75 | 6.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.49 | 6.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.57 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.28 | 4.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.78 | 3.8% | 1 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $17.35 | 3.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.27 | 3.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.85 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $451.36 | 21 |
| Consulting Fee | $17.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $124.15 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $124.15 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.16 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.49 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
122 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 214 | 58 |
| Ozempic | Semaglutide | 178 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 51 |
| Allopurinol | Allopurinol | 152 | 45 |
| Famotidine | Famotidine | 138 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 38 |
| Synthroid | Levothyroxine Sodium | 122 | 24 |
| Valsartan | Valsartan | 114 | 24 |
| Farxiga | Dapagliflozin Propanediol | 102 | 23 |
| Gabapentin | Gabapentin | 102 | 31 |
| Methylprednisolone | Methylprednisolone | 101 | 74 |
| Prednisone | Prednisone | 101 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 28 |
| Alprazolam | Alprazolam | 91 | 26 |
| Mirtazapine | Mirtazapine | 91 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 23 |
| Repatha Sureclick | Evolocumab | 84 | suppressed |
| Trulicity | Dulaglutide | 84 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 25 |
| Losartan Potassium | Losartan Potassium | 76 | 24 |
| Clonazepam | Clonazepam | 74 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 73 | 57 |
| Irbesartan | Irbesartan | 73 | 21 |
| Omeprazole | Omeprazole | 70 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 16 |
| Trazodone Hcl | Trazodone Hcl | 66 | 16 |
| Sertraline Hcl | Sertraline Hcl | 65 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 22 |
| Mounjaro | Tirzepatide | 60 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 20 |
| Eliquis | Apixaban | 54 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 13 |
| Montelukast Sodium | Montelukast Sodium | 51 | 14 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 22 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Xyosted | Testosterone Enanthate | 44 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 40 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 11 |
| Belsomra | Suvorexant | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Estradiol | Estradiol | 32 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Armodafinil | Armodafinil | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Lisinopril | Lisinopril | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | 11 |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 18 |
| Meloxicam | Meloxicam | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $468.71 · 22 records | PFIZER INC. | ALVESCO, AZMIRO, CUTAQUIG, EVENITY, GEMTESA, HORIZANT, KISUNLA, LEQVIO, MOUNJARO, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, REXULTI, Sunosi, UNITHROID, VRAYLAR, Xembify, Xhance, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error